Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2018

  • ID: 4590352
  • Report
  • 82 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bioneer Corp
  • Boehringer Ingelheim GmbH
  • IMV Inc
  • MimiVax LLC
  • Optimum Therapeutics LLC
  • Oxford Vacmedix UK Ltd
  • MORE
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2018

Summary:

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 21 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2018, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules.

The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 10 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Pancreatic Cancer, Prostate Cancer, Bladder Cancer, Melanoma, Autoimmune Disorders, Bone Metastasis, Glioblastoma Multiforme (GBM), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Ovarian Cancer, Solid Tumor, Colon Carcinoma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Peritoneal Cancer and Recurrent Glioblastoma Multiforme (GBM).

Furthermore, this report also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
  • The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bioneer Corp
  • Boehringer Ingelheim GmbH
  • IMV Inc
  • MimiVax LLC
  • Optimum Therapeutics LLC
  • Oxford Vacmedix UK Ltd
  • MORE
Introduction

Report Coverage

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development

Biomics Biotechnologies Co Ltd

Bioneer Corp

Boehringer Ingelheim GmbH

IMV Inc

MimiVax LLC

Optimum Therapeutics LLC

Oxford Vacmedix UK Ltd

Polyplus-Transfection SA

Stemline Therapeutics Inc

Vaxeal Holding SA

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles

Antibody to Target Survivin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGA-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1644 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1740 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPX-Survivac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-2C2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OVM-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UC-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Autoimmune Diseases, Glioblastoma Multiforme and Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Colon Carcinoma and Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones

Featured News & Press Releases

Jun 13, 2018 : Immunotherapy Vaccine Shows Great Promise in Treating Brain Cancer Patients

Jun 05, 2018 : Stemline Therapeutics Announces Positive Data Presentations on SL-701 at ASCO

Jun 03, 2018 : IMV Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting

May 29, 2018 : Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

May 21, 2018 : MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma

May 17, 2018 : Stemline Therapeutics Announces Presentation of SL-701 Clinical Data at the Upcoming ASCO Annual Meeting

May 15, 2018 : MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2018 : Immunovaccine to Highlight Clinical Data for Its Lead Candidate in Oral Presentation at 54th Annual Meeting of the American Society of Clinical Oncology

Apr 26, 2018 : Stemline Therapeutics Announces Clinical Presentation of SL-701 at the Upcoming ASCO Annual Meeting

Apr 25, 2018 : Incyte to Present Data from DeCidE1 trial at the 2018 ASCO Annual Meeting

Mar 28, 2018 : Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL

Mar 08, 2018 : Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies

Dec 05, 2017: Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

Dec 05, 2017: Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

Nov 16, 2017: Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Biomics Biotechnologies Co Ltd, H2 2018

Pipeline by Bioneer Corp, H2 2018

Pipeline by Boehringer Ingelheim GmbH, H2 2018

Pipeline by IMV Inc, H2 2018

Pipeline by MimiVax LLC, H2 2018

Pipeline by Optimum Therapeutics LLC, H2 2018

Pipeline by Oxford Vacmedix UK Ltd, H2 2018

Pipeline by Polyplus-Transfection SA, H2 2018

Pipeline by Stemline Therapeutics Inc, H2 2018

Pipeline by Vaxeal Holding SA, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biomics Biotechnologies Co Ltd
  • Bioneer Corp
  • Boehringer Ingelheim GmbH
  • IMV Inc
  • MimiVax LLC
  • Optimum Therapeutics LLC
  • Oxford Vacmedix UK Ltd
  • Polyplus-Transfection SA
  • Stemline Therapeutics Inc
  • Vaxeal Holding SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll